

WHAT IS CLAIMED IS:

1. A method for treating IL-6-mediated inflammation in a patient, comprising:
administering an IL-6 antagonist to a patient with IL-6-mediated inflammation at a dose that is sufficient to reduce inflammation without causing immune suppression.
2. The method of claim 1, wherein the patient has an elevated pre-treatment C-reactive protein (CRP) level.
3. The method of claim 2, wherein the pre-treatment CRP level of the patient is at least 2 mg/L.
4. The method of claim 3, wherein the pre-treatment CRP level of the patient is at least 4 mg/L.
5. The method of claim 4, wherein the pre-treatment CRP level of the patient is at least 6 mg/L.
6. The method of claim 5, wherein the pre-treatment CRP level of the patient is at least 10 mg/L.
7. The method of any of the above claims, wherein the patient has an elevated pre-treatment serum IL-6 level.
8. The method of claim 7, wherein the pre-treatment serum IL-6 level of the patient is at least 2 pg/mL.
9. The method of claim 8, wherein the pre-treatment serum IL-6 level of the patient is at least 4 pg/mL.
10. The method of claim 9, wherein the pre-treatment serum IL-6 level of the patient is at least 5 pg/mL.
11. The method of claim 10, wherein the pre-treatment serum IL-6 level of the patient is at least 10 pg/mL.
12. The method of any of the above claims, wherein the inflammation is measured by the level of C-reactive protein (CRP).
13. The method of claim 12, wherein the post-treatment CRP level is no more than 2 mg/L.
14. The method of claim 13, wherein the post-treatment CRP level is no more than 1 mg/L.

15. The method of claim 12, wherein the CRP level is decreased by at least 50% as compared to pre-treatment levels.
16. The method of claim 15, wherein the CRP level is decreased by at least 70% as compared to pre-treatment levels.
17. The method of claim 16, wherein the CRP level is decreased by at least 80% as compared to pre-treatment levels.
18. The method of claim 17, wherein the CRP level is decreased by at least 90% as compared to pre-treatment levels.
19. The method of any of the above claims, wherein the immune suppression is measured by absolute neutrophil count (ANC).
20. The method of claim 19, wherein the post-treatment ANC is at least 500 cells/ μ L.
21. The method of claim 20, wherein the post-treatment ANC is at least 1000 cells/ μ L.
22. The method of claim 21, wherein the post-treatment ANC is at least 1500 cells/ μ L.
23. The method of claim 21, wherein the post-treatment ANC is at least 2000 cells/ μ L.
24. The method of claim 19, wherein the ANC is decreased by no more than 2000 cells/ μ L as compared to pre-treatment levels.
25. The method of claim 24, wherein the ANC is decreased by no more than 1500 cells/ μ L as compared to pre-treatment levels.
26. The method of claim 25, wherein the ANC is decreased by no more than 1000 cells/ μ L as compared to pre-treatment levels.
27. The method of claim 26, wherein the ANC is decreased by no more than 500 cells/ μ L as compared to pre-treatment levels.
28. The method of claim 19, wherein the ANC is decreased by no more than 50% as compared to pre-treatment levels.
29. The method of claim 28, wherein the ANC is decreased by no more than 40% as compared to pre-treatment levels.
30. The method of claim 29, wherein the ANC is decreased by no more than 30% as compared to pre-treatment levels.

- 31.** The method of claim 30, wherein the ANC is decreased by no more than 20% as compared to pre-treatment levels.
- 32.** The method of claim 31, wherein the ANC is decreased by no more than 10% as compared to pre-treatment levels.
- 33.** The method of claim 19, wherein the ANC is not decreased as compared to pre-treatment levels.
- 34.** The method of any of the above claims, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is no more than 30% of the monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.
- 35.** The method of claim 34, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is no more than 20% of the monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.
- 36.** The method of claim 35, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is no more than 10% of the monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.
- 37.** The method of any one of claims 1 to 33, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is about 25% of a monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.
- 38.** The method of any one of claims 1 to 33, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is about 20% of a monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.
- 39.** The method of any one of claims 1 to 33, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is about 15% of a monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.
- 40.** The method of any one of claims 1 to 33, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is about 10% of a monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.
- 41.** The method of any one of claims 1 to 33, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is about 5% of a monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.

42. The method of any of the above claims, wherein the IL-6 antagonist is an anti-IL-6 antibody.
43. The method of claim 42, wherein the anti-IL-6 antibody is COR-001.
44. The method of claim 43, wherein COR-001 is administered intravenously at a monthly equivalent dose of 2 - 40 mg.
45. The method of claim 43, wherein COR-001 is administered intravenously at a monthly equivalent dose of about 2 mg.
46. The method of claim 43, wherein COR-001 is administered intravenously at a monthly equivalent dose of about 4 mg.
47. The method of claim 43, wherein COR-001 is administered intravenously at a monthly equivalent dose of about 6 mg.
48. The method of claim 43, wherein COR-001 is administered intravenously at a monthly equivalent dose of about 10 mg.
49. The method of claim 43, wherein COR-001 is administered intravenously at a monthly equivalent dose of about 20 mg.
50. The method of claim 43, wherein COR-001 is administered intravenously at a monthly equivalent dose of about 40 mg.
51. The method of claim 43, wherein COR-001 is administered subcutaneously at a monthly equivalent dose of 3-70 mg.
52. The method of claim 43, wherein COR-001 is administered subcutaneously at a monthly equivalent dose of about 3 mg.
53. The method of claim 43, wherein COR-001 is administered subcutaneously at a monthly equivalent dose of about 7 mg.
54. The method of claim 43, wherein COR-001 is administered subcutaneously at a monthly equivalent dose of about 10 mg.
55. The method of claim 43, wherein COR-001 is administered subcutaneously at a monthly equivalent dose of about 17 mg.
56. The method of claim 43, wherein COR-001 is administered subcutaneously at a monthly equivalent dose of about 35 mg.

57. The method of claim 43, wherein COR-001 is administered subcutaneously at a monthly equivalent dose of about 70 mg.
58. The method of claim 42, wherein the anti-IL-6 antibody is siltuximab.
59. The method of claim 58, wherein siltuximab is administered intravenously at a monthly equivalent dose of 50-500 mg.
60. The method of claim 58, wherein siltuximab is administered intravenously at a monthly equivalent dose of about 50 mg.
61. The method of claim 58, wherein siltuximab is administered intravenously at a monthly equivalent dose of about 100 mg.
62. The method of claim 58, wherein siltuximab is administered intravenously at a monthly equivalent dose of about 150 mg.
63. The method of claim 58, wherein siltuximab is administered intravenously at a monthly equivalent dose of about 200 mg.
64. The method of claim 58, wherein siltuximab is administered intravenously at a monthly equivalent dose of about 300 mg.
65. The method of claim 58, wherein siltuximab is administered intravenously at a monthly equivalent dose of about 500 mg.
66. The method of claim 58, wherein siltuximab is administered subcutaneously at a monthly equivalent dose of 80-800 mg.
67. The method of claim 58, wherein siltuximab is administered subcutaneously at a monthly equivalent dose of about 80 mg.
68. The method of claim 58, wherein siltuximab is administered subcutaneously at a monthly equivalent dose of about 160 mg.
69. The method of claim 58, wherein siltuximab is administered subcutaneously at a monthly equivalent dose of about 240 mg.
70. The method of claim 58, wherein siltuximab is administered subcutaneously at a monthly equivalent dose of about 320 mg.
71. The method of claim 58, wherein siltuximab is administered subcutaneously at a monthly equivalent dose of about 480 mg.

72. The method of claim 58, wherein siltuximab is administered subcutaneously at a monthly equivalent dose of about 800 mg.
73. The method of claim 42, wherein the anti-IL-6 antibody is gerilimzumab.
74. The method of claim 73, wherein gerilimzumab is administered intravenously at a monthly equivalent dose of 0.075-1.8 mg.
75. The method of claim 73, wherein gerilimzumab is administered intravenously at a monthly equivalent dose of about 0.075 mg.
76. The method of claim 73, wherein gerilimzumab is administered intravenously at a monthly equivalent dose of about 0.12 mg.
77. The method of claim 73, wherein gerilimzumab is administered intravenously at a monthly equivalent dose of about 0.3 mg.
78. The method of claim 73, wherein gerilimzumab is administered intravenously at a monthly equivalent dose of about 0.6 mg.
79. The method of claim 73, wherein gerilimzumab is administered intravenously at a monthly equivalent dose of about 0.9 mg.
80. The method of claim 73, wherein gerilimzumab is administered intravenously at a monthly equivalent dose of about 1.8 mg.
81. The method of claim 73, wherein gerilimzumab is administered subcutaneously at a monthly equivalent dose of 0.125-3 mg.
82. The method of claim 73, wherein gerilimzumab is administered subcutaneously at a monthly equivalent dose of about 0.125 mg.
83. The method of claim 73, wherein gerilimzumab is administered subcutaneously at a monthly equivalent dose of about 0.2 mg.
84. The method of claim 73, wherein gerilimzumab is administered subcutaneously at a monthly equivalent dose of about 0.5 mg.
85. The method of claim 73, wherein gerilimzumab is administered subcutaneously at a monthly equivalent dose of about 1 mg.
86. The method of claim 73, wherein gerilimzumab is administered subcutaneously at a monthly equivalent dose of about 1.5 mg.

87. The method of claim 73, wherein gerilimzumab is administered subcutaneously at a monthly equivalent dose of about 3 mg.
88. The method of claim 42, wherein the anti-IL-6 antibody is sirukumab.
89. The method of claim 88, wherein sirukumab is administered intravenously at a monthly equivalent dose of 1.5-60 mg.
90. The method of claim 88, wherein sirukumab is administered intravenously at a monthly equivalent dose of about 1.5 mg.
91. The method of claim 88, wherein sirukumab is administered intravenously at a monthly equivalent dose of about 3 mg.
92. The method of claim 88, wherein sirukumab is administered intravenously at a monthly equivalent dose of about 6 mg.
93. The method of claim 88, wherein sirukumab is administered intravenously at a monthly equivalent dose of about 12 mg.
94. The method of claim 88, wherein sirukumab is administered intravenously at a monthly equivalent dose of about 36 mg.
95. The method of claim 88, wherein sirukumab is administered intravenously at a monthly equivalent dose of about 60 mg.
96. The method of claim 88, wherein sirukumab is administered subcutaneously at a monthly equivalent dose of 2.5-100 mg.
97. The method of claim 88, wherein sirukumab is administered subcutaneously at a monthly equivalent dose of about 2.5 mg.
98. The method of claim 88, wherein sirukumab is administered subcutaneously at a monthly equivalent dose of about 5 mg.
99. The method of claim 88, wherein sirukumab is administered subcutaneously at a monthly equivalent dose of about 10 mg.
100. The method of claim 88, wherein sirukumab is administered subcutaneously at a monthly equivalent dose of about 20 mg.
101. The method of claim 88, wherein sirukumab is administered subcutaneously at a monthly equivalent dose of about 60 mg.

- 102.** The method of claim 88, wherein sirukumab is administered subcutaneously at a monthly equivalent dose of about 100 mg.
- 103.** The method of claim 42, wherein the anti-IL-6 antibody is clazakizumab.
- 104.** The method of claim 103, wherein clazakizumab is administered intravenously at a monthly equivalent dose of 3-60 mg.
- 105.** The method of claim 103, wherein clazakizumab is administered intravenously at a monthly equivalent dose of about 3 mg.
- 106.** The method of claim 103, wherein clazakizumab is administered intravenously at a monthly equivalent dose of about 6 mg.
- 107.** The method of claim 103, wherein clazakizumab is administered intravenously at a monthly equivalent dose of about 12 mg.
- 108.** The method of claim 103, wherein clazakizumab is administered intravenously at a monthly equivalent dose of about 24 mg.
- 109.** The method of claim 103, wherein clazakizumab is administered intravenously at a monthly equivalent dose of about 36 mg.
- 110.** The method of claim 103, wherein clazakizumab is administered intravenously at a monthly equivalent dose of about 60 mg.
- 111.** The method of claim 103, wherein clazakizumab is administered subcutaneously at a monthly equivalent dose of 5-100 mg.
- 112.** The method of claim 103, wherein clazakizumab is administered subcutaneously at a monthly equivalent dose of about 5 mg.
- 113.** The method of claim 103, wherein clazakizumab is administered subcutaneously at a monthly equivalent dose of about 10 mg.
- 114.** The method of claim 103, wherein clazakizumab is administered subcutaneously at a monthly equivalent dose of about 20 mg.
- 115.** The method of claim 103, wherein clazakizumab is administered subcutaneously at a monthly equivalent dose of about 40 mg.
- 116.** The method of claim 103, wherein clazakizumab is administered subcutaneously at a monthly equivalent dose of about 60 mg.

117. The method of claim 103, wherein clazakizumab is administered subcutaneously at a monthly equivalent dose of about 100 mg.
118. The method of claim 42, wherein the anti-IL-6 antibody is olokizumab.
119. The method of claim 118, wherein olokizumab is administered intravenously at a monthly equivalent dose of 1.8-60 mg.
120. The method of claim 118, wherein olokizumab is administered intravenously at a monthly equivalent dose of about 1.8 mg.
121. The method of claim 118, wherein olokizumab is administered intravenously at a monthly equivalent dose of about 3.6 mg.
122. The method of claim 118, wherein olokizumab is administered intravenously at a monthly equivalent dose of about 9 mg.
123. The method of claim 118, wherein olokizumab is administered intravenously at a monthly equivalent dose of about 18 mg.
124. The method of claim 118, wherein olokizumab is administered intravenously at a monthly equivalent dose of about 45 mg.
125. The method of claim 118, wherein olokizumab is administered intravenously at a monthly equivalent dose of about 60 mg.
126. The method of claim 118, wherein olokizumab is administered subcutaneously at a monthly equivalent dose of 3-100 mg.
127. The method of claim 118, wherein olokizumab is administered subcutaneously at a monthly equivalent dose of about 3 mg.
128. The method of claim 118, wherein olokizumab is administered subcutaneously at a monthly equivalent dose of about 6 mg.
129. The method of claim 118, wherein olokizumab is administered subcutaneously at a monthly equivalent dose of about 15 mg.
130. The method of claim 118, wherein olokizumab is administered subcutaneously at a monthly equivalent dose of about 30 mg.
131. The method of claim 118, wherein olokizumab is administered subcutaneously at a monthly equivalent dose of about 72 mg.

- 132.** The method of claim 118, wherein olokizumab is administered subcutaneously at a monthly equivalent dose of about 100 mg.
- 133.** The method of claim 42, wherein the anti-IL-6 antibody is VX30 (VOP-R003; Vaccinex).
- 134.** The method of claim 133, wherein VX30 (VOP-R003; Vaccinex) is administered intravenously.
- 135.** The method of claim 133, wherein VX30 (VOP-R003; Vaccinex) is administered subcutaneously.
- 136.** The method of claim 42, wherein the anti-IL-6 antibody is EB-007 (EBI-029; Eleven Bio).
- 137.** The method of claim 136, wherein EB-007 (EBI-029; Eleven Bio) is administered intravenously.
- 138.** The method of claim 136, wherein EB-007 (EBI-029; Eleven Bio) is administered subcutaneously.
- 139.** The method of claim 42, wherein the anti-IL-6 antibody is FM101 (Femta Pharmaceuticals, Lonza).
- 140.** The method of claim 139, wherein FM101 (Femta Pharmaceuticals, Lonza) is administered intravenously.
- 141.** The method of claim 139, wherein FM101 (Femta Pharmaceuticals, Lonza) is administered subcutaneously.
- 142.** The method of any one of claims 1 to 41, wherein the IL-6 antagonist is an anti-IL-6R antibody.
- 143.** The method of claim 142, wherein the anti-IL-6R antibody is tocilizumab.
- 144.** The method of claim 143, wherein tocilizumab is administered intravenously at a monthly equivalent dose of 50-500 mg.
- 145.** The method of claim 143, wherein tocilizumab is administered intravenously at a monthly equivalent dose of about 50 mg.
- 146.** The method of claim 143, wherein tocilizumab is administered intravenously at a monthly equivalent dose of about 100 mg.

- 147.** The method of claim 143, wherein tocilizumab is administered intravenously at a monthly equivalent dose of about 150 mg.
- 148.** The method of claim 143, wherein tocilizumab is administered intravenously at a monthly equivalent dose of about 250 mg.
- 149.** The method of claim 143, wherein tocilizumab is administered intravenously at a monthly equivalent dose of about 350 mg.
- 150.** The method of claim 143, wherein tocilizumab is administered intravenously at a monthly equivalent dose of about 500 mg.
- 151.** The method of claim 143, wherein tocilizumab is administered subcutaneously at a monthly equivalent dose of 80-800 mg.
- 152.** The method of claim 143, wherein tocilizumab is administered subcutaneously at a monthly equivalent dose of about 80 mg.
- 153.** The method of claim 143, wherein tocilizumab is administered subcutaneously at a monthly equivalent dose of about 160 mg.
- 154.** The method of claim 143, wherein tocilizumab is administered subcutaneously at a monthly equivalent dose of about 240 mg.
- 155.** The method of claim 143, wherein tocilizumab is administered subcutaneously at a monthly equivalent dose of about 400 mg.
- 156.** The method of claim 143, wherein tocilizumab is administered subcutaneously at a monthly equivalent dose of about 560 mg.
- 157.** The method of claim 143, wherein tocilizumab is administered subcutaneously at a monthly equivalent dose of about 800 mg.
- 158.** The method of claim 142, wherein the anti-IL-6R antibody is sarilumab.
- 159.** The method of claim 158, wherein sarilumab is administered intravenously at a monthly equivalent dose of 12-120 mg.
- 160.** The method of claim 158, wherein sarilumab is administered intravenously at a monthly equivalent dose of about 12 mg.
- 161.** The method of claim 158, wherein sarilumab is administered intravenously at a monthly equivalent dose of about 24 mg.

- 162.** The method of claim 158, wherein sarilumab is administered intravenously at a monthly equivalent dose of about 48 mg.
- 163.** The method of claim 158, wherein sarilumab is administered intravenously at a monthly equivalent dose of about 60 mg.
- 164.** The method of claim 158, wherein sarilumab is administered intravenously at a monthly equivalent dose of about 72 mg.
- 165.** The method of claim 158, wherein sarilumab is administered intravenously at a monthly equivalent dose of about 120 mg.
- 166.** The method of claim 158, wherein sarilumab is administered subcutaneously at a monthly equivalent dose of 20-200 mg.
- 167.** The method of claim 158, wherein sarilumab is administered subcutaneously at a monthly equivalent dose of about 20 mg.
- 168.** The method of claim 158, wherein sarilumab is administered subcutaneously at a monthly equivalent dose of about 40 mg.
- 169.** The method of claim 158, wherein sarilumab is administered subcutaneously at a monthly equivalent dose of about 80 mg.
- 170.** The method of claim 158, wherein sarilumab is administered subcutaneously at a monthly equivalent dose of about 100 mg.
- 171.** The method of claim 158, wherein sarilumab is administered subcutaneously at a monthly equivalent dose of about 120 mg.
- 172.** The method of claim 158, wherein sarilumab is administered subcutaneously at a monthly equivalent dose of about 200 mg.
- 173.** The method of claim 142, wherein the anti-IL-6R antibody is vobarilizumab.
- 174.** The method of claim 173, wherein vobarilizumab is administered intravenously at a monthly equivalent dose of 4-120 mg.
- 175.** The method of claim 173, wherein vobarilizumab is administered intravenously at a monthly equivalent dose of about 4 mg.
- 176.** The method of claim 173, wherein vobarilizumab is administered intravenously at a monthly equivalent dose of about 6 mg.

177. The method of claim 173, wherein vobarilizumab is administered intravenously at a monthly equivalent dose of about 30 mg.
178. The method of claim 173, wherein vobarilizumab is administered intravenously at a monthly equivalent dose of about 60 mg.
179. The method of claim 173, wherein vobarilizumab is administered intravenously at a monthly equivalent dose of about 84 mg.
180. The method of claim 173, wherein vobarilizumab is administered intravenously at a monthly equivalent dose of about 120 mg.
181. The method of claim 173, wherein vobarilizumab is administered subcutaneously at a monthly equivalent dose of 7-200 mg.
182. The method of claim 173, wherein vobarilizumab is administered subcutaneously at a monthly equivalent dose of about 7 mg.
183. The method of claim 173, wherein vobarilizumab is administered subcutaneously at a monthly equivalent dose of about 10 mg.
184. The method of claim 173, wherein vobarilizumab is administered subcutaneously at a monthly equivalent dose of about 50 mg.
185. The method of claim 173, wherein vobarilizumab is administered subcutaneously at a monthly equivalent dose of about 100 mg.
186. The method of claim 173, wherein vobarilizumab is administered subcutaneously at a monthly equivalent dose of about 140 mg.
187. The method of claim 173, wherein vobarilizumab is administered subcutaneously at a monthly equivalent dose of about 200 mg.
188. The method of any one of claims 1 to 41, wherein the IL-6 antagonist is a JAK inhibitor.
189. The method of any one of claims 1 to 41, wherein the IL-6 antagonist is a STAT3 inhibitor.
190. The method of any of the above claims, wherein the patient has a hepcidin-mediated disorder.
191. The method of any one of claims 1 to 189, wherein the patient has kidney disease.
192. The method of claim 191, wherein the patient has chronic kidney disease.

- 193.** The method of claim 192, wherein the patient has KDOQI stage 1-5 chronic kidney disease.
- 194.** The method of claim 193, wherein the patient has KDOQI stage 3-5 chronic kidney disease.
- 195.** The method of claim 194, wherein the patient is not on dialysis.
- 196.** The method of claim 193, wherein the patient has KDOQI stage 5 chronic kidney disease.
- 197.** The method of claim 196, wherein the patient is on dialysis.
- 198.** The method of claim 192, wherein the patient has cardiorenal syndrome (CRS).
- 199.** The method of claim 198, wherein the patient has CRS Type 4.
- 200.** The method of any one of claims 1 to 189, wherein the patient has cardiovascular disease.
- 201.** The method of claim 200, wherein the patient has diuretic resistant heart failure.
- 202.** The method of claim 200, wherein the patient has congestive heart failure (CHF).
- 203.** The method of claim 202, wherein the patient has congestive heart failure (CHF) with reduced ejection fraction.
- 204.** The method of claim 202, wherein the patient has congestive heart failure (CHF) with mid-range ejection fraction.
- 205.** The method of claim 202, wherein the patient has congestive heart failure (CHF) with preserved ejection fraction.
- 206.** The method of claim 200, wherein the patient has acute coronary syndrome.
- 207.** The method of claim 200, wherein the patient has atherosclerosis.
- 208.** The method of any one of claims 1 to 189, wherein the patient has anemia.
- 209.** The method of claim 208, wherein the patient has anemia of chronic disease.
- 210.** The method of claim 208, wherein the patient has iron-refractory iron-deficiency anemia (IRIDA).
- 211.** The method of any one of claims 1 to 189, wherein the patient has diabetes.
- 212.** The method of claim 211, wherein the patient has type II diabetes.

- 213.** The method of claim 211, wherein the patient has insulin-resistant diabetes.
- 214.** The method of any one of claims 1 to 189, wherein the patient has liver disease.
- 215.** The method of claim 214, wherein the patient has non-alcoholic steatohepatitis (NASH).
- 216.** The method of any one of claims 1 to 189, wherein the patient has osteoporosis.
- 217.** The method of any one of claims 1 to 189, wherein the patient has depression.
- 218.** The method of any one of claims 1 to 189, wherein the patient has asthma.
- 219.** The method of any one of claims 1 to 189, wherein the patient has neuroinflammatory disorder.
- 220.** The method of claim 219, wherein the patient has Alzheimer's disease.
- 221.** The method of claim 219, wherein the patient has Parkinson's disease.
- 222.** The method of claim 219, wherein the patient has multiple sclerosis.
- 223.** The method of claim 219, wherein the patient has amyotrophic lateral sclerosis (ALS).
- 224.** The method of any one of claims 1 to 189, wherein the patient has age-related macular degeneration (AMD).
- 225.** The method of any one of claims 1 to 189, wherein the patient has cancer.
- 226.** The method of claim 225, wherein the cancer is selected from the group consisting of: solid tumors, small cell lung cancer, non-small cell lung cancer, hematological cancer, multiple myeloma, leukemia, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), lymphomas, Hodgkin's lymphoma and hepatic adenoma.
- 227.** The method of any one of claims 1 to 189, wherein the patient has skin disease.
- 228.** The method of any one of claims 1 to 189, wherein the method prevents aging in the patient.
- 229.** A method for treating inflammation in a patient with cardiovascular disease, comprising:
administering an IL-6 antagonist to a patient with cardiovascular disease and CRP level greater than 2 mg/L at a dose that is sufficient to reduce CRP levels to 2 mg/L or less without causing neutropenia.

230. The method of claim 229, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is no more than 30% of the monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.

231. The method of claim 230, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is no more than 20% of the monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.

232. The method of claim 231, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is no more than 10% of the monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.

233. A method for treating inflammation in a patient with chronic kidney disease (CKD), comprising:

administering an IL-6 antagonist to a patient with CKD and a CRP level greater than 2 mg/L at a dose that is sufficient to reduce CRP levels to 2 mg/L or less without causing neutropenia.

234. The method of claim 233, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is no more than 30% of the monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.

235. The method of claim 234, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is no more than 20% of the monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.

236. The method of claim 235, wherein the IL-6 antagonist is administered at a monthly equivalent dose that is no more than 10% of the monthly equivalent dose for treating rheumatoid arthritis with the same IL-6 antagonist.